Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, PULMONX CORPORATION reported revenue of $90M, up 8.0% year over year. Operating margin was -59.3% and net margin -59.7%, on a free-cash-flow margin of -36.3% with capital expenditure at 0.5% of revenue. Every figure is computed directly from LUNG's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $90M | -59.3% | -59.7% |
| FY2024 | $84M | -68.9% | -67.3% |
| FY2023 | $69M | -90.2% | -88.6% |
| FY2022 | $54M | -109.3% | -109.8% |
| FY2021 | $48M | -97.7% | -100.5% |
How does LUNG compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.